EU Commission opens consultations on Merger Regs review
The European Commission has launched a public consultation on the functioning of the EC Merger Regulation (Council Regulation 139/2004), which sets out the rules for merger control in the European Economic Area.
The purpose of the review is to evaluate how the rules on jurisdictional thresholds and referral mechanisms have worked in practice during the fours years the Regulation has been applied. Based on the response to the consultation, the Commission's own experience in applying the Regulation and feedback from national competition authorities, it will prepare a report to the EU Council of Ministers by July 2009. The Commission welcomes comments to the consultation up to December 1.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze